Klin Onkol 2008; 21(Suppl 1): 230-233.
Clinical and genetic heterogeneity is a characteristic feature of multiple myeloma (MM). Despite intensive efforts to clarify the pathogenesis of MM, mechanisms of MM development remain enigmatic. Novel methodological approaches, such as gene expression profi ling (GEP), are valuable tools in order to link clinical endpoints, such as response to treatment and surfoval, with th molecular and genetic heterogenity of the disease. The main challenge of current studies is to defi ne diagnostic and prognostic relevance of GEP technologies in a clinical management.
